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Introduction: In liver fibrosis activation of hepatic stellate cells (HSC) comprises
phenotypical change into profibrotic and myofibroplastic cells with increased
contraction and secretion of extracellular matrix (ECM) proteins. The small GTPase
RhoA orchestrates cytoskeleton formation, migration, and mobility via non-receptor
tyrosine-protein kinase c-SRC (cellular sarcoma) in different cells. Furthermore, RhoA
and its downstream effector Rho-kinase also play a crucial role in hepatic stellate cells
and hepatic fibrogenesis. Matrix stiffness promotes HSC activation via cytoskeleton
modulation. This study investigated the interaction of c-SRC and RhoA under different
matrix stiffness conditions.
Methods: Liver fibrosis was induced in rats using bile duct ligation (BDL), thioacetamide
(TAA) or carbon tetrachloride (CCl4) models. mRNA levels of albumin, PDGF-R, RHOA,
COL1A1, and αSMAwere analyzed via qRT-PCR. Western Blots using phospho-specific
antibodies against p-c-SRC418 and p-c-SRC530 analyzed the levels of activating and
inactivating c-SRC, respectively. LX2 cells and hepatocytes were cultured on acrylamide
gels of 1 and 12 kPa or on plastic to mimic non-fibrotic, fibrotic, or cirrhotic environments
then exposed to SRC-inhibitor PP2. Overexpression of RhoA was performed by
transfection using RhoA-plasmids. Additionally, samples from cirrhotic patients and
controls were collected at liver transplantations and tumor resections were analyzed for
RhoA and c-SRC protein expression by Western Blot.
Results: Transcription of albumin and RhoA was decreased, whereas transcription and
activation of c-SRC was increased in hepatocytes cultured on 12 kPa compared to 1
kPa gels. LX2 cells cultured on 12 kPa gels showed upregulation of RHOA, COL1A1, and
αSMAmRNA levels. Inhibition of c-SRC by PP2 in LX2 cells led to an increase in COL1A1
and αSMA most prominently in 12 kPa gels. In LX2 cells with RhoA overexpression,
c-SRC inhibition by PP2 failed to improve fibrosis. RhoA expression was significantly
elevated in human and experimental liver fibrosis, while c-SRC was inactivated.
Conclusions: This study shows that c-SRC is inactive in activated myofibroblast-like
HSC in liver cirrhosis. Inactivation of c-SRC is mediated by a crosstalk with RhoA upon
hepatic stellate cell activation and fibrosis progression.
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INTRODUCTION
End-stage liver disease is characterized by fibrosis and loss
of organ function, and is one of the leading causes of death
worldwide (World Health Organisation, 2002; National Institute
on Alcohol Abuse and Alcoholism, 2014). In chronic liver injury,
hepatic stellate cells (HSC) get activated, proliferate, and migrate
within liver tissue (Rockey, 1997). Moreover, activated HSCs
are the major contributors to liver fibrogenesis by extracellular
matrix (ECM) synthesis (Mederacke et al., 2013). The small
GTPase RhoA is a master regulator protein and mediates
HSC activity and motility by signaling downstream to effectors
Rho-kinase (ROCK) or mDia1 (Thumkeo et al., 2013). In
liver fibrosis, upregulation of the RhoA/ROCK axis leads to
increased vascular contractility and portal pressure (Hennenberg
et al., 2006; Trebicka et al., 2007). The RhoA/ROCK signaling
exerts these effects via activated HSCs (Trebicka et al., 2010).
Inhibition of RhoA/ROCK activity in liver fibrosis reduces
portal pressure and attenuates hepatic fibrosis by induction of
HSC senescence (Trebicka et al., 2010; Klein et al., 2012a,b).
Besides the RhoA/ROCK axis, RhoA also interacts with the
cytosolic tyrosine kinase c-SRC via mDia1 (Yamana et al., 2006).
c-SRC is a transmembraneous regulator, which plays a role
in focal adhesion complexes and cytoskeletal dynamics and
mediates proliferatition via the platelet-derived growth factor
receptor (PDGF-R) (Brown and Cooper, 1996; Yamana et al.,
2006; Huveneers and Danen, 2009). Furthermore, pro-oncogenic
properties make c-SRC an important target in cancer research
(Musumeci et al., 2012; Gargalionis et al., 2014; Varkaris et al.,
2014).
The regulation of the downstream signaling of RhoA via
either ROCK or mDia1/c-SRC plays an important role in
the dynamics and contractility of intracellular stress fibers.
While stimulation of the RhoA/mDia1/c-SRC-axis leads to
actin polymerization, the stimulation of the RhoA/ROCK-
axis leads to actomyosin contractility and inhibits actin
depolymerization (Takai et al., 2001; Quack et al., 2009). In
migration and contraction of activated HSCs the signaling
via RhoA/ROCK is well-investigated. However, little is
known about the role of c-SRC and the interplay with
RhoA in liver fibrosis in general and in activated HSCs in
particular.
In this work, we show for the first time the changes
exerted by liver fibrosis in the expression of activating and
inactivating phosphorylation sites of c-SRC in both human
and rat liver samples. Furthermore, we demonstrate that c-SRC
plays a decisive role in RhoA and cytoskeletal protein activity




All animal testing was carried out using wild type rats. Our
studies were approved by the committee responsible for animal
studies in North Rhine-Westphalia (LANUV reference number
84-02.04.2014.A137).
Cholestatic Model of Fibrosis
Bile duct ligation (BDL) was performed in rats with an initial
body weight between 180 and 200 g as previously described
(Heller et al., 2003). Sham-operated rats served as controls.
Experiments were performed after a 4 week interval to allow
development of liver fibrosis.
Toxic Model of Fibrosis
Rats with an initial body weight between 80 and 100 g were
administered carbon tetrachloride (CCl4) via inhalation for 14–
16 weeks as described previously (Granzow et al., 2014). Age-
matched rats who did not receive CCl4 served as controls.
Additionally, rats with an initial body weight between 200 and
250 g were orally administered thioacetamide (TAA) weekly for
18 weeks as described previously (Verbeke et al., 2014).
Tissue Collection
After induction of liver fibrosis, the rats were anesthetized and
laparotomy was performed for tissue collection. The livers were
cut into fragments and stored at −80◦C until they were used
for qRT-PCR and western blot analysis as described previously
(Trebicka et al., 2008, 2010).
Human Liver Samples
Human liver samples were taken during liver transplantation
from patients with alcohol-induced cirrhosis. Liver samples from
non-cirrhotic patients who underwent liver resection served
as controls. No patient or donor received catecholamines,
angiotensin receptor antagonists or ACE inhibitors prior to
transplantation. All samples were snap frozen after excision. The
use of human liver samples was approved by the Human Ethics
Committee of the University of Bonn (reference number 029/13).
All subjects gave written informed consent in accordance with the
Declaration of Helsinki.
Isolation of Primary Hepatocytes and
Hepatic Stellate Cells
Primary rat hepatocytes and hepatic stellate cells were isolated
and cultured as described previously (Herman et al., 1988;
Wojtalla et al., 2012; Granzow et al., 2014). Viability and purity
were routinely more than 95%. For early activation of HSCs,
cells were harvested at day 10 and for advanced activation
with differentiation to myofibroblast-like phenotype, cells were
harvested at third passage.
Cell Culture
Snap-frozen LX2 cells and primary rat hepatic stellate cells were
incubated with cell culture medium (DMEM + 20% FBS +
Penicillin/Streptomycin) in 250ml plastic flasks at 37◦C. After
reaching 80% confluency, cells were passaged with a 1:3 split
ratio. Detachment was achieved by incubating the cells with
0.05% Trypsin/EDTA solution (solved in PBS) for 5min at 37◦C.
Before transfection, LX2 cells were incubated with transfection
media (DMEM with 10% FBS) for 24 h. Plasmids with wildtype
RhoA, constitutively active RhoA and dominant negative RhoA
were kindly provided by Prof. Dr. Fürst (Institute for Cell
Biology, University of Bonn, Germany). Fifteen microliter of
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the respective plasmid and 37.5µl of lipofectamine were then
incubated for 20min with 3.6ml transfection media. Cell media
was then aspirated and the cells were incubated with the
plasmid/lipofectamine mix, which was carefully added drop-
wise. After 4 h, cells were again incubated in transfection media
and harvested 3 days later. Efficacy of transfection was tested
using qRT-PCR.
Inhibition of c-SRC
For inhibition of c-SRC 4-Amino-3-(4-chlorophenyl)-1-
(t-butyl)-1H-pyrazolo[3,4-d]pyrimidine (PP2; Sigma-Aldrich,
Munich, Germany) has been used to blunt c-SRC mediated
effects (Hanke et al., 1996; Yoshizumi et al., 2000). Ten
micrometer of PP2 were added to the cell culture medium and
cells were incubated for 2 days before harvesting.
Polyacrylamide Gels
Either snap-frozen LX2 cells or isolated rat hepatocytes were
seeded on fibrinogen-coated polyacrylamide (PAA) gels of
variable stiffness. Matrices were prepared on 12mm cover slips
in 6-well cell culture plates as previously described (Olsen
et al., 2011). Briefly, gels were cross-linked using a Spectroline
Microprocessor controlled UV Cross-linker (Thermo Scientific,
Waltham, USA). Prepared gels were then coated with fibronectin
(Sigma-Aldrich, Munich, Germany). Healthy parenchymatous
conditions were simulated by soft matrices with 1 kPa shear
modulus, while matrices used to simulate stiff conditions had a
shear modulus of 12 kPa. Cell culture was then performed on
these gels as described above.
qRT-PCR
Liver homogenates from either fibrotic or non-fibrotic rats were
prepared using previously described methods (Trebicka et al.,
2010). RNA was isolated from samples using the Qiazol reagent
as instructed by the manufacturer (Qiagen, Hilden, Germany)
(Trebicka et al., 2013; Anadol et al., 2015). The following assays
provided by Applied Biosystems (Foster City, USA) were used:
ACTA2 (αSMA, Hs00426835_g1), COL1A1 (Hs00164004_m1),
Src (Rn01418228_m1) PDGFRB (Hs01019589_m1), RHOA (for
human; Hs01051295-m1), and RhoA (for rat; Rn04219609_m1).
Albumin (Rn-Alb_1_SG) was provided by Qiagen (Hilden,
Germany). Samples were normalized to 18s rRNA.
Western Blotting
Snap-frozen cells and liver samples were processed as previously
described using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gels and nitrocellulose membranes
(Kwiecinski et al., 2011). Equal protein loading was assured
using Ponceau-S staining. GAPDH served as endogenous
control of protein expression. Membranes were incubated with
rabbit-anti-p-c-SRC (Tyr418) from Invitrogen (Darmstadt,
Germany), rabbit-anti-c-SRC, rabbit-anti-p-c-SRC (Tyr530),
mouse-anti-RhoA, and rabbit-anti-GAPDH primary antibodies
and corresponding peroxidase-coupled secondary antibodies
from Santa Cruz Biotechnology (Heidelberg, Germany).
Results were analyzed using Chemi-Smart digital detection
(PeqLab, Biotechnologies, Erlangen, Germany) after enhanced
chemiluminescence (ECL, Amersham, UK).
Statistical Analysis
Group size was at least n = 5 for each group. Graphs are
presented as means ± standard deviation and p < 0.05 were
considered statistically significant. Western blots were measured
using digital densitometry software (Bio-1D v.15.02, Vilber
Lourmat, Marne-la-Vallée, France) and the respective density
of each band was calculated. The fibrosis groups were tested
for significance to their corresponding controls using Mann-
Whitney U test. In qPCR experiments, 2−ddCT was calculated
and normalized to the respective control group. Plotting of
diagrams and statistic analysis were performed using GraphPad
Prism version 4.00 for Windows (GraphPad Software, La Jolla,
California, USA).
RESULTS
RhoA and c-SRC Crosstalk in Hepatocytes
Rat hepatocytes, which were cultivated on PAA gels with a shear
modulus of 12 kPa, simulating stiff liver tissue, showed reduced
function marked by a significant decrease in transcription
levels of albumin compared to hepatocytes cultivated on 1 kPa
gels (Figure 1A). Reduced hepatocyte function further led to
a significant downregulation of RhoA transcription under stiff
conditions, while mRNA levels of c-Src were increased in these
cells (Figure 1A).
Besides transcription of c-Src, also the activation of the c-
SRC protein was altered in hepatocytes cultivated on PAA gels
with 12 kPa. Phosphorylation at tyrosine 488 (p-c-Src418), the c-
SRC activating phosphorylation site, was significantly increased
and phosphorylation at tyrosine 530, the c-SRC inactivating
phosphorylation site, showed a trend to be decreased under stiff
conditions (Figure 1B).
RhoA and c-SRC Crosstalk in Human
Derived HSC Cell Line LX2 under Stiff
Conditions
In contrast to hepatocytes, cultivation on PAA gels with
shear modulus of 12 kPa led to stimulation and activation of
hepatic stellate cells (HSC). Both, proliferation as shown by
transcriptional levels of Pdgf-r, as well as activation and collagen
secretion as shown by the surrogate marker αSma and collagen
1 mRNA levels, were increased when cells were cultivated on
PAA gels with stiffness of 12 kPa compared to cells cultivated
on PAA gels with stiffness of 1 kPa (Figure 2A). Furthermore,
transcription of RhoA was increased significantly, but less
pronounced, in LX2 cells under stiff conditions (Figure 2A).
Incubation with PP2, a selective inhibitor of the c-SRC
tyrosine kinases, decreased transcriptional levels of RhoA and
of the HSC activation markers collagen 1 and αSma even under
soft conditions when LX2 cells were cultivated on PAA gels with
shear modulus of 1 kPa (Figure 2B). On PAA gels with 12 kPa
stiffness incubation with PP2 revealed similar results compared
to the experiments performed on 1 kPa gels. However, the effect
of c-SRC inhibition by PP2 on reduction of RhoA, collagen 1, and
αSmamRNA levels was stronger in LX2 cells cultivated on 12 kPa
PAA gels (Figure 2C).
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FIGURE 1 | RhoA and c-SRC crosstalk in hepatocytes. (A) Hepatocytes
were incubated on gels with a shear modulus of 1 kPa, simulating healthy liver
tissue, and with a shear modulus of 12 kPa, simulating fibrotic tissue.
Hepatocyte function was reduced under stiff conditions as shown by albumin
transcription levels. Transcription of RhoA was decreased, while c-Src mRNA
was increased under stiff conditions. (B) Activating phosphorylation
(p-c-SRC418) of c-SRC was increased, while inactivating (p-c-SRC530) was
decreased under stiff conditions in hepatocytes.
RhoA and c-SRC Crosstalk in Hepatic
Stellate Cells under Extremely Stiff
Conditions
The high matrix stiffness prevailing in plastic cell culture flasks
simulates the extremely stiff matrix conditions in liver cirrhosis.
Under these conditions the c-SRC activation in primary rat
HSCs drops with progressive HSC activation as shown by a
significant increase in p-c-SRC530 and a decrease in p-c-SRC418
(Figure 3A). Total protein levels of c-SRC remained unchanged
upon progressive HSC activation under extremely stiff conditions
(Figure 3A).
Inhibition of c-SRC by PP2 under extremely stiff conditions
led to a significant upregulation of RhoA mRNA (Figure 3B).
Furthermore, PP2 significantly increased HSC activation as
demonstrated by αSmamRNA levels. Additionally, also collagen
FIGURE 2 | RhoA and c-SRC crosstalk in human derived HSC cell line
LX2 under fibrotic conditions. (A) Human derived hepatic stellate cell line
(HSC) LX2 were incubated on gels with shear modulus of 1 kPa, simulating
healthy liver tissue, and with shear modulus of 12 kPa, simulating fibrotic
tissue. Transcription of proliferative (PDGF-R) and activation (αSMA) markers
was increased under stiff conditions. Stiff conditions stimulated LX2 cells to
increase collagen production. RhoA was slightly increased by mRNA levels
under stiff conditions. (B) PP2 administration reduced RhoA, Collagen 1 and
αSMA mRNA levels under soft conditions. (C) Similarly, in LX2 cell incubated
on 12 kPa gels, PP2 administration led to decreased transcription of RhoA,
Collagen 1 and αSMA. However, the effect of PP2 in LX2 cells on 12 kPa gels
was more pronounced than in LX2 cells on 1 kPa.
production showed a trend toward an increase in transcriptional
level (Figure 3B).
RhoA and c-SRC Crosstalk in Experimental
and Human Liver Cirrhosis
In bile duct ligated (BDL) rats, a model for cholestatic liver
cirrhosis, the inactivating phosphorylation at tyrosine 530 of c-
SRC was significantly increased compared to sham operated rats
(Figures 4A,B). As a consequence, phosphorylation at tyrosine
418 of c-SRC was significantly decreased in these animals, while
total protein levels of c-SRC remained unchanged upon BDL
(Figures 4A,B). In addition, RhoA was highly upregulated in
BDL rats (Figures 4A,B).
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FIGURE 3 | RhoA and c-SRC crosstalk in hepatic stellate cells under
cirrhotic conditions. (A) Primary rat hepatic stellate cells (HSC) were
cultivated on plastic, simulating extremely stiff conditions. For early activation
of HSCs, cells were harvested at day 10 and for advanced activation to
myofibroblast-like phenotype, cells were harvested at third passage.
Inactivating phosphorylation at tyrosine 530 of c-SRC was increased in
activated myofibroblast-like HSCs, while activating phosphorylation at tyrosine
418 of c-SRC showed a trend toward a decrease. Overall c-SRC protein did
not change upon HSC activation progress. (B) Inhibition of c-SRC by PP2 led
to increased mRNA levels of RhoA, Collagen 1 and αSMA in activated
myofibroblast-like HSCs.
Carbon tetrachloride (CCl4) and thioacetomide (TAA)
intoxication are both models for toxic liver cirrhosis. Parallel to
the results observed in BDL rats, phosphorylation at tyrosine
530 of c-SRC was significantly increased, while phosphorylation
at tyrosine 418 of c-SRC was significantly decreased in
CCl4 (Figures 4C,D) and TAA (Figures 4E,F) intoxicated rats
compared to untreated control rats. Also in experimental models
of toxic liver cirrhosis levels of total c-SRC remained unchanged,
while RhoA was significantly increased (Figures 4C–F).
Changes in c-SRC activation in models of experimental liver
damage mirrored the situation in human liver cirrhosis. In liver
samples of cirrhotic patients c-SRC activating phosphorylation at
tyrosine 418 was significantly downregulated compared to non-
cirrhotic control liver samples (Figures 4G,H). As a consequence
c-SRC inactivating phosphorylation at tyrosine 530 was increased
in liver samples of cirrhotic patients. As shown for experimental
liver cirrhosis, also in human liver cirrhosis RhoA expression is
highly upregulated compared to the non-cirrhotic control liver
samples (Figures 4G,H).
These data suggest a marked counterplay of RhoA and
c-SRC expression in human and experimental liver cirrhosis
(Figure 5A).
DISCUSSION
In the present study, we demonstrate for the first time that the
activity of c-SRC decreases with progressive liver fibrogenesis
and hepatic stellate cell (HSC) activation (Figure 5B). We could
show that this effect on c-SRC is regulated by a counterplay with
RhoA, which, in contrast, is upregulated with progressing HSC
activation (Figure 5A). Thereby, c-SRC inactivation was reached
by increased phosphorylation at tyrosine 530 and decreased
phosphorylation at tyrosine 418, while total protein levels of SRC
in HSCs were unchanged upon progressing liver damage. Since
this crosstalk of RhoA and c-SRC could be observed in cholestatic
and toxic models of liver cirrhosis, as well as in alcohol-induced
human liver cirrhosis, our data suggest that the mechanisms are
independent of the etiology.
SRC consists of four SRC homology (SH) domains and
phosphorylation at tyrosine 530 on SH2 leads to inactivation
of SRC. Dephosphorylation at tyrosine 530 by different
kinases, such as SH2-containing phosphatases, allows
autophosphorylation at tyrosine 418/419 on SH1, which includes
the kinase domain, and leads to activation of SRC (reviewed
in Yeatman, 2004). Members of the SRC family kinases have
been broadly investigated in cancer due to their pro-oncogenic
characteristics (Musumeci et al., 2012; Gargalionis et al., 2014;
Varkaris et al., 2014). While first results for c-SRC targeting have
been reported in the treatment of idiopathic pulmonary fibrosis,
systemic sclerosis and glioblastoma (Beyer and Distler, 2013;
Ceccherini et al., 2015), its role in liver fibrosis progression is not
yet understood.
To simulate either healthy or fibrotic environments, we
chose to incubate hepatocytes and hepatic stellate cells on
polyacrylamide matrices of a defined shear modulus, since
it has been shown that a stiff environment is required for
differentiation of HSCs to a myofibroblastic phenotype (Olsen
et al., 2011). Plastic cell culture flasks are extremely stiff and out
of the physiologic range, but provide a useful model system to
mimic cells receiving maximal stimulation from a stiff matrix.
Hepatic stellate cells that grow in these containers can often only
be observed in a highly activated and fully transdifferentiated
myofibroblastic state. Results obtained from cells incubated on
plastic are therefore restricted to describe only end-stage liver
disease. Polyacrylamide matrices allow a better analysis of cells,
since different stages of fibrosis progression can be simulated
under more physiologically relevant conditions (Olsen et al.,
2011).
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FIGURE 4 | RhoA and c-SRC crosstalk in experimental and human liver cirrhosis. Protein expression of phosphorylated c-SRC and RhoA in cholestatic BDL
(A,B), toxic CCl4 (C,D), or TAA (E,F) intoxication liver cirrhosis models, as well as in samples of human liver tissue (G,H) showed increased inactivation of c-SRC
(p-c-SRC530) in liver cirrhosis. In contrast, activating phosphorylation (p-c-SRC418) was decreased. RhoA was highly upregulated in experimental and human liver
cirrhosis. Controls were sham operated rats for the BDL model, untreated rats for CCl4 and TAA model an liver biopsies from non-cirrhotic patients.
Inhibition of c-SRC by PP2 as a therapeutic approach may
be promising only in early fibrotic stages, when HSCs are
migrating. In this stage c-SRC is still active and drives cytoskeletal
dynamics and cell motility by stimulation of actin polymerization
(Takai et al., 2001; Quack et al., 2009). Furthermore, c-SRC is
increased in monocytes and macrophages andmediates secretion
of pro-inflammatory cytokines (Sarang et al., 2011; Yokoi et al.,
2011), which may contribute to HSC activation upon liver
damage.
In contrast, in progressive liver disease activated
HSCs develop a myofibroblast-like phenotype. Activated
myofibroblast-like HSCs are contractile and drive hepatic
fibrogenesis (Friedman, 2003; Mederacke et al., 2013). These
effects are mediated by upregulated RhoA/Rho-kinase signaling
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FIGURE 5 | Regulation of RhoA and c-SRC activity upon progression of
liver fibrosis. (A) Scheme of the RhoA and c-SRC crosstalk in hepatic stellate
cells (HSC). c-SRC activation primary stimulates migration of HSCs and
activation of RhoA leads to contraction and collagen production. Therefore,
c-SRC seems to play a important role in early stages of fibrosis, when HSCs
are proliferating and migrating. In contrast, RhoA plays a pivotal role in
progressed fibrosis, when HSC phenotype changes into a myofibroblast-like
phenotype. (B) Progression of HSC activation into myofibroblast-like cells and
the corresponding cell culture conditions mimicking fibrosis progression. Upon
HSC activation RhoA becomes highly upregulated, while c-SRC activation is
suppressed.
upon liver damage (Trebicka et al., 2007, 2010). Our group has
demonstrated several times that the signaling cascade via JAK2,
RhoA, and Rho-kinase signaling is upregulated in liver fibrosis
and located mainly in myofibroblast-like activated HSC (Zhou
et al., 2006; Granzow et al., 2014; Klein et al., 2015). With the
current study we show that increased RhoA activity leads to
decreased c-SRC activity with progressive HSC activation. At this
stage, inhibition of c-SRC by PP2 failed to improve transcription
of fibrogenic markers, probably since c-SRC activity is already
low under these conditions, due to the increased phosphorylation
at tyrosine 530. This data suggests that the phenotype change of
HSC is mediated by a crosstalk of RhoA and c-SRC.
ECM components are responsible for increased matrix
stiffness in liver fibrosis and may influence expression of c-SRC
via growth factor or hyaluronan receptors (e.g., CD44) or focal
adhesion complexes (Nikitovic et al., 2013). Furthermore, ECM
components may have direct paracrine and endocrine effects
on HSC function and intracellular signaling in liver fibrosis
(reviewed in Wells, 2013; Karsdal et al., 2015). Besides increased
matrix stiffness, which is only one factor of liver fibrosis, the
crosstalk of RhoA, and c-SRC may be triggered by other factors
such as proinflammatory or profibrotic cytokines upon liver
disease progression. Also regulatory miRNAs in response to
inflammatory stimuli could play a role. However, the molecular
mechanisms which regulate the crosstalk of RhoA and c-SRC
remain unclear and should be investigated in future studies.
Besides inhibition of c-SRC, PP2 has been described to have
a weak affinity to inhibit other kinases like JAK2 (Hanke et al.,
1996), which is an upstream regulator of RhoA activity (Granzow
et al., 2014; Klein et al., 2015). However, the doses of PP2 used in
our in vitro experiments was very low and much higher doses
would be of need to inhibit the JAK2/RhoA axis (Hanke et al.,
1996).
In conclusion, this study provides insight into the role of
matrix stiffness on c-SRC activity and the crosstalk of RhoA and
c-SRC upon progressing liver damage. Furthermore, the usage
of PAA gels of different elasticities, simulating different stages of
fibrosis progression, proves to be useful for in vitro experiments
to investigate molecular and pathomechanistic changes triggered
by liver fibrosis progression.
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